FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to rheumatology, and can be used for prediction of achieving an acceptable quality of life in psoriatic arthritis. A complex of indicators is determined, such as: patient's age, number of swollen joints, CRP and achievement of remission within 1 year, after which they are assessed in points and based on the obtained data, the probability of achieving an acceptable quality of life in psoriatic arthritis is determined by formula. If the value is less than 0.5, a low probability of achieving an acceptable quality of life in psoriatic arthritis is predicted, and with values equal to 0.5 and higher, high probability of achieving an acceptable quality of life in psoriatic arthritis is predicted.
EFFECT: method enables predicting the achievement of an acceptable quality of life both at present and in the long term by determining a complex of the most significant physical and psychoemotional parameters and their assessment.
1 cl, 1 dwg, 2 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF PREDICTING ACHIEVEMENT OF MINIMAL DISEASE ACTIVITY DURING THERAPY IN TREATMENT OF PATIENTS WITH PSORIATIC ARTHRITIS | 2022 |
|
RU2808550C1 |
METHOD FOR ASSESSING POSSIBILITY OF ACHIEVING MINIMUM DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS | 2024 |
|
RU2829416C1 |
METHOD FOR DETERMINING PSORIATIC ARTHRITIS ACTIVITY | 2020 |
|
RU2746884C1 |
METHOD FOR ASSESSING THE RISK OF JOINT EROSIONS IN PATIENTS WITH PSORIATIC ARTHRITIS | 2022 |
|
RU2791661C1 |
METHOD FOR ASSESSING RISK OF SACROILIITIS PROGRESSION IN PATIENTS WITH EARLY PSORIATIC ARTHRITIS | 2024 |
|
RU2837143C1 |
METHOD FOR DETERMINING INDICATIONS TO BEGINNING OF RECEPTION OF GENETIC ENGINEERING BIOLOGICAL PREPARATIONS WITH INEFFECTIVENESS OF BASIC ANTI-INFLAMMATORY PREPARATIONS IN EARLY FORMS OF PSORIATIC ARTHRITIS | 2020 |
|
RU2731807C1 |
METHOD FOR RAPID ASSESSMENT OF AXIAL SKELETON INVOLVEMENT RISK IN EARLY FORMS OF PSORIATIC ARTHRITIS | 2020 |
|
RU2724276C1 |
METHOD FOR ASSESSING THE EFFECTIVENESS OF TREATMENT OF PSORIATIC ARTHRITIS USING ANTIOXIDANT SYSTEM PARAMETERS | 2021 |
|
RU2762105C1 |
METHOD FOR DETERMINING CLINICALLY SIGNIFICANT FATIGUE IN A PATIENT WITH RHEUMATOID ARTHRITIS AGAINST THE BACKGROUND OF 5-YEAR THERAPY WITH BASIC ANTI-INFLAMMATORY DRUGS OR BASIC ANTI-INFLAMMATORY DRUGS IN COMBINATION WITH GENETICALLY ENGINEERED BIOLOGICAL DRUGS AND/OR PSYCHOPHARMACOTHERAPY AND CONCOMITANT ANXIETY-DEPRESSIVE SPECTRUM DISORDER | 2021 |
|
RU2760220C1 |
METHOD FOR DETERMINING REMITTANCE IN A PATIENT SUFFERING RHEUMATOID ARTHRITIS WITH UNDERLYING 5-YEAR THERAPY OF BASIC ANTI-INFLAMMATORY PREPARATIONS OR BASIC ANTI-INFLAMMATORY PREPARATIONS IN COMBINATION WITH GENETICALLY ENGINEERED BIOLOGICAL PREPARATIONS AND ACCOMPANYING COMORBID ANXIETY-DEPRESSIVE DISORDER | 2019 |
|
RU2701638C1 |
Authors
Dates
2025-03-26—Published
2024-11-15—Filed